Clinical Trial Update: A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

This document describes a Phase II clinical trial evaluating a PD-L1 inhibitor in combination with anti-VEGF therapy for unresectable or metastatic melanoma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)
• anti-VEGF therapy

Snippet

Sponsor: Elizabeth Buchbinder, MD | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING